Who Owns Philips?

Philips has committed to becoming carbon neutral in its operations by 2030. The company has been carbon neutral in its logistics since 2020 and sources 100% renewable electricity for its operations since 2020. Philips has set science-based targets validated by the Science Based Targets initiative for Scope 1, 2, and 3 emissions.

Philips is a pioneer in circular economy practices for medical devices. The company offers refurbished medical imaging systems through its Diamond Select program, extending the lifecycle of MRI and CT equipment. Philips has implemented take-back programs for medical equipment and designs products for upgradeability rather than replacement.

Philips does not hold B Corp certification. The company publishes an annual ESG report as part of its integrated annual report, detailing environmental performance, social impact, and governance metrics. The 2025 report covers carbon emissions, waste reduction, diversity metrics, and supply chain responsibility.

The Respironics recall raised questions about Philips' quality control and regulatory compliance. The FDA issued a Form 483 with inspectional observations at the Murrysville, Pennsylvania facility in November 2021. The consent decree requires Philips to retain independent quality system experts to oversee compliance improvements. Philips has stated that it has remediated more than 99% of the actionable registered CPAP and BiPAP sleep therapy devices globally as of 2025.

No greenwashing controversies have been documented against Philips. The company's environmental claims are supported by third-party verified science-based targets and circular economy programs with measurable outcomes.

Philips has received recognition for its medical technology innovation. The company's MRI, CT, and ultrasound systems have received FDA clearance and CE marking, and several products have won industry awards from medical imaging publications including AuntMinnie and Diagnostic Imaging.

Philips' product designs have received iF Design Awards and Red Dot Design Awards consistently over multiple years. The company's healthcare products and consumer devices have been recognized for user experience and industrial design.

Philips was ranked among the top 10 medical device companies globally by revenue in 2025 by Medical Design and Outsourcing magazine. The company was also included in the Dow Jones Sustainability Index for its ESG performance.

The compact cassette, developed by Philips in 1962, was inducted into the IEEE Milestones in Electrical Engineering list. The compact disc, co-developed with Sony in 1982, received similar recognition.

The Philips Respironics recall is the most significant controversy in the company's history. In June 2021, Philips initiated a voluntary recall of approximately 5.5 million CPAP, BiPAP, and mechanical ventilator devices due to degradation of polyester-based polyurethane (PE-PUR) sound abatement foam. The degraded foam could release particles and volatile organic compounds that users could inhale or ingest. The recall affected devices sold between 2009 and 2021.

The FDA classified the recall as Class I, the most serious type, indicating a reasonable probability of serious injury or death. The FDA received more than 100,000 medical device reports associated with the recalled devices between April 2021 and April 2024, including reports of deaths. Philips stated that its testing concluded the devices were "not expected to result in appreciable harm to health in patients," a claim the FDA did not fully endorse.

In January 2024, Philips agreed to a consent decree with the US Department of Justice, acting on behalf of the FDA. The consent decree prohibits Philips from selling new Respironics sleep apnea devices in the United States until the company demonstrates compliance with FDA manufacturing requirements. Philips must retain independent quality system experts, complete remediation of all recalled devices, and pay disgorgement of profits from sales of medically necessary devices. Philips recorded a EUR 363 million provision in Q4 2023 for remediation costs.

As of February 2026, more than 99% of actionable registered CPAP and BiPAP sleep therapy devices have been remediated globally. Remediation of ventilator devices remains ongoing. The consent decree is expected to take several years to fully resolve, meaning Philips cannot sell new sleep apnea devices in the US market until compliance is achieved.

Philips also faced an EU antitrust fine in 2012 for participating in a cathode-ray tube price-fixing cartel. The European Commission fined Philips EUR 313 million for its role in the cartel, which lasted from 1996 to 2006. Philips appealed the fine but lost in 2015.

In 2013, Philips cancelled the sale of its audio and video operations to Funai Electric, leading to legal disputes. Funai sued Philips for breach of contract. The parties reached a settlement in 2014.

In 2023, Philips announced the elimination of 10,000 jobs over two years as part of a restructuring program following the Respironics recall and financial losses. The workforce reduction was completed in 2025.